Vis enkel innførsel

Epilepsy and cannabidiol: a guide to treatment

dc.contributor.authorArizmanoglou, Alexis
dc.contributor.authorBrandl, Ulrich
dc.contributor.authorCross, Helen
dc.contributor.authorGil-nagel, Antonio
dc.contributor.authorLagae, Lieven
dc.contributor.authorLandmark, Cecilie Johannessen
dc.contributor.authorSpecchio, Nicola
dc.contributor.authorNabbout, Rima
dc.contributor.authorThiele, Elisabeth
dc.contributor.authorGubbay, Oliver
dc.date.accessioned2020-02-28T15:35:41Z
dc.date.accessioned2020-03-28T12:44:44Z
dc.date.available2020-02-28T15:35:41Z
dc.date.available2020-03-28T12:44:44Z
dc.date.issued2020-12-19
dc.identifier.citationArizmanoglou, Brandl, Cross, Gil-nagel, Lagae L, Landmark CJL, Specchio, Nabbout R, Thiele, Gubbay. Epilepsy and cannabidiol:a guide to treatment. Epileptic disorders. 2020;22(1):1-14en
dc.identifier.issn1294-9361
dc.identifier.issn1294-9361
dc.identifier.urihttps://hdl.handle.net/10642/8335
dc.description.abstractThe growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.en
dc.description.sponsorshipA. Arzimanoglou receives salary support from the University Hospitals of Lyon (HCL). His work is also partly supported by the European Union grant for the coordination of the EpiCARE European Reference Network. He has a mission of Editor-in-Chief for the ILAE educational journal Epileptic Disorders and of Associate Editor for the European Journal of Paediatric Neurology. He is an investigator on research grants awarded to HCL, France and Sant Joan de Deu Hospital Barcelona from the Caixa Foundation, GW Pharma and UCB; he has received travel expenses or consulting fees from Advicenne Pharma, Amzell, Arvelle, Biomarin, Eisai, GW Pharma, Lündbeck, Sanofi, Shire, Takeda, UCB Pharma, Zogenix. R. Nabbout receives salary from APHP and university Paris Descartes. She reports grants from EU (EJP-RD, Horizons 2020, and FP7), research grants from Shire, Livanova, Eisai and UCB, consulting and lecturer fees from Eisai, Advicenne Pharma, Takeda, Biomarin, Lundbeck, Zogenix, novartis, and GW pharma, outside the submitted work. Antonio Gil-Nagel has received support from Zogenix, Bilal, Stoke Therapeutics, GW, UCB, Arvelle Therapeutics, Sanofi, Marinus Pharma. Nicola Specchio has received grant support and fees for advisory board participation from GW Pharma. J. Helen Cross has acted as an investigator for studies with GW Pharma, Zogenix, Vitaflo and Marinius. She has been a speaker and on advisory boards for GW Pharma, Zogenix, and Nutricia; all remuneration has been paid to her department. Her work is supported by the NIHR Biomedical Research Centre at Great Ormond Street Hospital & University College London. U. Brandl, Lieven Lagae, Cecilie Johannessen Landmark, Oliver Gubbay, and EA. Thiele have no disclosures. The workshop was supported by an educational grant from the Fundació Sant Joan de Déu (Barcelona, Spain) and the Association ESEFNP (Lyon, France).en
dc.language.isoenen
dc.publisherWileyen
dc.relation.ispartofseriesEpileptic Disorders;Volume 22, Issue 1, February 2020
dc.rightsThis work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International Licenseen
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.subjectEpilepsyen
dc.subjectCannabisen
dc.subjectCannabidiolen
dc.subjectOilen
dc.subjectGuidelinesen
dc.subjectDravet syndromeen
dc.titleEpilepsy and cannabidiol: a guide to treatmenten
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2020-02-28T15:35:41Z
dc.description.versionpublishedVersionen
dc.identifier.doihttps://doi.org/10.1684/epd.2020.1141
dc.identifier.cristin1798543
dc.source.journalEpileptic disorders


Tilhørende fil(er)

Thumbnail
Filnavn:
Arzimanoglou-epilepsy_and_cann ...
Størrelse:
394.4Kb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
Med mindre annet er angitt, så er denne innførselen lisensiert som This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License